8-K
Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On September 14, 2026, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended July 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1
PRESS RELEASE pbsv_ex991.htm EXHIBIT 99.1
September 14, 2026
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026 DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and nine months ended July 31, 2026 were approximately $2.3 million and $7.3 million, respectively, representing increases of approximately $0.4 million and $0.5 million compared to the same periods last year.
For the three and nine months ended July 31, 2026, the Company reported a net loss of $14 thousand and net income of approximately $252 thousand, respectively, representing improvements of approximately $190 thousand and $352 thousand, respectively, compared with the corresponding periods of the prior year.
“Our Q3 results demonstrate the strength of our client relationships and the value of our specialized regulatory and compliance capabilities. By sharpening our focus on markets where our expertise creates a distinct competitive advantage and continuing to drive operating efficiencies, we meaningfully improved our financial performance. We remain confident in our ability to build on this progress and carry that momentum through the final quarter of the year,” said Victor Sanchez, Chief Executive Officer.
About Pharma-Bio Serv, Inc.